Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial

What Was Tested

The paper reports a study of Teriparatide, published as a randomized controlled trial.

Osteogenesis imperfecta causes multiple fractures throughout life, causing substantial morbidity.

Who Took Part

The abstract describes 2025, adults taking part.

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Multicenter open-label, parallel-group, randomized clinical trial, conducted between May 17, 2017, and March 21, 2025, in adults attending one of 27 referral centers with a clinical diagnosis of osteogenesis imperfecta.

How the Study Was Run

In design terms this was a randomized, open-label, multicenter and parallel-group study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Teriparatide study: the adults and staff both knew the treatment.

More than one site took part, so the adults came from several places.

The Teriparatide group and the comparison group ran side by side rather than switching.

Bone mineral density (BMD) was measured by dual x-ray absorptiometry and bone turnover by serum procollagen type 1 N-terminal propeptide and C-terminal telopeptide of type 1 collagen.

Fractures were confirmed by skeletal imaging.

Several measures of health-related quality of life were assessed.

In the standard care group, bisphosphonates and other bone-targeted medicines could be used but teriparatide and other bone anabolic drugs were prohibited.

What Was Measured

Topics PubMed links to this paper include Bone Density, Bone Density Conservation Agents, Bone Remodeling, Fractures, Bone, Osteogenesis Imperfecta, Peptide Fragments and Procollagen.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Teriparatide in 2025, adults.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (JAMA), a journal based in United States.

More context: the Teriparatide compound page, all human trials.